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Abstract
The King's College London (KCL) Infectious Diseases BioBank opened in 2007 and collects
peripheral venous blood (PVB) from individuals infected with pathogens including human
immunodeficiency virus (HIV). PVBs are fractionated into plasmas, lymphocytes and DNA and are
then frozen. All donations are from subjects who have given 'open consent' so samples can be used
for virtually any type of biomedical research. The HIV component of the BioBank contains samples
from over 400 donations from 138 HIV+ patients. Thus, the KCL Infectious Diseases BioBank -
together with establishments such as the Spanish HIV BioBank - is likely to expedite translational
research into this infection.
Commentary
A recent Correspondence  described the Spanish HIV
BioBank [1], and here we would like to draw the attention
of the readers of Retrovirology to a similar initiative in Lon-
don, the United Kingdom (UK). The fact that high-quality
tissue collections from patients will undoubtedly play an
important role in translational research led King's College
London (KCL) to open an Infectious Diseases (ID)
BioBank in 2007. Current interests of the KCL ID BioBank
are pathogens of local and international importance,
namely: HIV, hepatitis B virus and a variety of bacteria.
This Commentary describes the structure and operation of
the KCL ID BioBank, with particular reference to the HIV
archive.
Location and management of the BioBank
The BioBank is embedded within the KCL Department of
Infectious Diseases and is affiliated to Guy's and St Tho-
mas' Hospitals National Health Service (NHS) Trust
which act as tissue collection centres (TCC). This NHS
Trust is one of five flagship Academic Health Centres in
the UK and hosts an NHS National Institute of Health
Research BioMedical Research Centre. The location of the
KCL ID BioBank is another key feature in addition to these
outstanding academic and clinical credentials: firstly, its
location permits the expansion of TCCs to other major
London teaching Hospitals (a third TCC at King's College
Hospital was opened in September 2009 and another at St
George's Hospital is planned for 2010). Secondly, the
local population is large (~7 million), diverse (~300 dif-
ferent languages are spoken), transient and suffers some
of the highest HIV infection rates in Europe. Indeed, one
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percent of women attending ante-natal clinics at St Tho-
mas' Hospital are HIV positive [2] and clinics at the three
TCCs care for around 5,000 HIV+ patients.
Like the Spanish HIV tissue collection, the KCL ID
BioBank has a director (JC), manager (RJW), and a gov-
ernance committee comprising of scientists and clini-
cians. The functions of this committee are to ensure that
the BioBank operates within current UK legislation, to
make policy decisions, and to assess the scientific merit of
research applications from academic or commercial inves-
tigators in Europe or the USA. It is also empowered to act
as a local research ethics committee and provide ethical
opinions for studies which apply to use BioBank samples.
BioBank operation and sample archive
Research nurses at the TCCs identify patients of interest as
well as hospital controls and inform them of the BioBank
via information sheets. At their next routine visit, subjects
are invited to participate. Healthy individuals are
recruited via posters and are incentivized with gift vouch-
ers. If subjects agree to participate, they sign consent forms
which detail possible risks or discomforts associated with
the procedures and the open-ended nature of the research
that their samples may be used for. All subjects have the
option to withdraw their permission and either leave their
samples in the repository or have them destroyed. Con-
sent forms are stored at the TCCs, and clinical samples
together with patient data sheets are anonymised.
The BioBank has permission to collect two categories of
clinical materials: (i) 'research samples' of PVB, urine and
faeces and, (ii) 'residual samples', i.e. any excess tissues,
biopsies, swabs or bodily fluids collected primarily for
diagnostic purposes. To date, only PVB samples have been
collected. Either type of sample can be collected from any
patient (who is a conscious adult, but neither a prisoner
nor mentally impaired) attending a routine clinical
appointment and who is suffering from any infectious or
inflammatory condition at any TCC registered by the
BioBank at any NHS location in England, Wales or North-
ern Ireland.
Up to seventy-milliliters of PVB are collected from HIV+
patients into EDTA Vacutainors™ and are then sent by
courier to the BioBank, together with anonymised clinical
details. Unlike some tissue collections, all KCL ID
BioBank samples are fractionated at one location by one
dedicated team using one set of standardized operating
procedures (SOPs) in a category III laboratory. PVBs are
separated into plasmas (1 ml aliquots), viable peripheral
blood mononuclear cells (PBMC: at 1 × 107/vial), as well
as cells for DNA extractions which comprise of whole PVB
cell pellets (residual from plasma preparations: 1 ml aliq-
uots) as well as granulocyte-rich cells (left over from
PBMC isolations: 1 ml aliquots). All fractions are frozen
to -80°C, and the PBMC samples are transferred to -
196°C liquid nitrogen stores located nearby. The BioBank
is equipped with a nucleic acid extraction robot and a lab-
oratory for quality control testing.
To date, the BioBank has collected PVB from 17 healthy
subjects (as of September 2009, n = 51 sample donations)
and 60 non-infected hospital controls (60 donations), 80
patients with hepatitis B (80 donations), 185 patients
with bacteraemias (185 donations), as well as from 143
patients with HIV (410 donations). TCCs recruit longitu-
dinal samples from HIV patients with interesting or unu-
sual clinical histories, specifically: (i) patients before and
after the initiation of highly active anti-retroviral therapy
(HAART),'new to HAART' (NTH); (ii) 'fast progressors'
(FP), defined as patients with <300 CD4+ cells/mm3
within four years of diagnosis; (iii) 'potential future long-
term non-progressors' (PF-LTNP: those with undetectable
or low viral loads, stable CD4+ cell numbers, long periods
of clinical latency etc.); and (iv) 'long-term non-progres-
sors' (LTNP) who fulfill the criteria of Grabar et al. 2009
[3]. The BioBank holds samples from ten (7.2%) LTNP
patients, and three (2.1%) 'elite' LTNP (Figure 1). For
comparison, rates of LTNP and elite LTNP amongst HIV+
patients in France are 0.4% and 0.05% respectively [3].
For the groups (iii) and (iv), patients who have never
received any anti-retroviral therapy are prioritized for
recruitment. Some patients can fall into two classifica-
tions (e.g. ~50% of fast progressors are about to receive
HAART when recruited). Longitudinal samples are col-
lected from all HIV patients This is an ongoing process. All
samples are taken when patients attend their routine clin-
ical appointment, and the frequency differs between
groups - NTH patients provide one or two pre-treatment
samples, then others at one, four, seven and twelve
months after starting therapy. Other groups donate sam-
ples at six monthly intervals.
In addition to archiving biological samples, the BioBank
maintains a database of clinical information on HIV
donors which includes: histories of CD4+ cell numbers
and plasma viral loads; dates of birth, last known HIV
negative result and first positive HIV test; ethnic origin;
gender; HAART received; and, any complicating infec-
tions. The database also contains sample processing infor-
mation (dates and times of: venepuncture, processing and
freezing) and details of numbers of aliquots stored or
transferred to researchers.
Distribution of samples
Researchers wishing to use BioBank samples are provided
with an information pack and must obtain a positive eth-
ical opinion and project approval by the governance com-
mittee. During this process they must specify the numberRetrovirology 2009, 6:98 http://www.retrovirology.com/content/6/1/98
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and types of samples which will be needed for their study.
BioBank samples are donated under 'open consent' so
that virtually any type of immunological, genetic or
microbiological testing can be performed on them. Exclu-
sions to this are studies which involve: (i) testing of safety
of cosmetics or consumer products; (ii) animal research;
(iii) investigations into the termination of pregnancy or
reproductive cloning; and, (iv) stem cells. There are no
commercial restrictions on the use of BioBank samples
(e.g. BioBank materials can be used to produce commer-
cial products by cloning).
After approval, UK researchers must sign a materials trans-
fer agreement (MTA) and the BioBank will then provide
samples together with a file containing the technical and
clinical information held in the database. An MTA suita-
ble for International collaborations which meets U.S.A.
and European governmental standards is currently being
prepared. Until present all such samples have been pro-
vided pro bono; however, a discretionary charge to subsi-
dize processing and storage costs will be introduced; and
it is anticipated that this will be incorporated into
researchers' grant applications. The types of studies cur-
rently using the BioBank include: investigations of DNA
polymorphisms of the restriction factor tetherin, the viral
permissivity factor ps20, functional studies of regulatory
T-cells, and HIV sequencing studies.
Quality control
A major challenge for all BioBanks is the continuous
improvement of quality-control measures. For example,
reliable RNA isolation was identified by the governance
committee of being of importance; thus, the PAXgene™
system is being introduced to stabilize PVB RNA at
venepuncture. More generally, standardization of SOPs
for processing biopsies [4,5] has led to the establishment
of the TuBaFrost association of European cancer tissue-
banks [6]. Such harmonization needs to be extended to
accommodate differing national legal and ethical regula-
tions [7]. Thus, the KCL ID BioBank is a member of the
International Society for Biological and Environmental
Repositories and has based its SOPs upon UNE-EN-ISO
9001:2000 in order to facilitate future inter-biobank net-
working capabilities.
Pre-analytical variation is a major source of experimental
error [8] and a major area of concern for biobanks is to
ensure that archived material does not become degraded
over time. PVBs are collected from HIV+ patients and
processed within a collection-to-freezer window of <24
hours and a target of freezing >75% of PVB samples
within 4 hours of venepuncture. All freezers are alarmed
and checked routinely for temperature fluctuations.
Plasma and PBMC samples released to researchers have
not undergone a freeze-thaw cycle and all DNA samples
are quantified and tested for the absence of polymerase
chain reaction (PCR) inhibitors (by amplification of the
human β-globin gene).
Random samples are also tested for the presence of viral
nucleic acids by PCR (PVB DNA) and reverse-transcrip-
tion-PCR (plasma) combined with cloning and sequenc-
ing. This has enabled the BioBank to establish a library of
>500 cloned and sequenced near full-length (1490 bp)
HIV-1 clade B gag genes, which are also available to exter-
nal researchers.
A subset of the KCL ID BioBank collection does not con-
form to the quality-control measures described above.
These include historic samples such as 1,000 HIV+ plas-
mas collected in the 1990s which are of unknown prove-
nance in terms of the number of freeze-thaw cycles they
have undergone. These are stored separately from the
main BioBank, and methods for assessing their integrity
are being explored. Plasma concentrations of soluble
CD40 can be useful biomarkers in this respect, but cannot
be used for HIV+ samples [9]; thus, plasma hormone lev-
els [10] are being investigated for this purpose.
Growth of the archive and future challenges
Whilst no single performance indicator can adequately
summarize the growth of the KCL ID BioBank over the
past two years, incidental statistics can be informative. In
Categories of HIV patients who have donated blood to the  BioBank Figure 1
Categories of HIV patients who have donated blood 
to the BioBank. NTH: new to HAART, this cohort also 
includes some patients who would equally fall into the FP or 
LTNP categories; FP: fast progressor (<300 CD4+ cells/mm3 
within three years of their last negative HIV test); PF-LTNP: 
potential future LTNP; LTNP: long term non-progressors 
(which includes 10 patients with CD4+ cell counts of >500 
cells/mm3 in eight years of follow-up and 3 'elite' LTNP with 
CD4 cell counts of >600 cells/mm3 for ten years of follow-up 
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each of the first two quarters of 2007, there were around
fifteen HIV+ patient visits per quarter whereas in the same
quarters of 2009 they were about sixty visits.
Pressing challenges which the BioBank will need to
address in the near future include: (i) data management,
as researchers are bound by the MTA to provide experi-
mental data back to the BioBank. This will lead to the
exciting possibility of multivariate analyses in silica across
a range of laboratory measurements of our HIV+ patients;
(ii) integration of the BioBank electronic database with
the bar-coded sample tubes via scanners: this will permit
the automated updating of records; and (iii) increasing
staffing levels.
Conclusion
This  Commentary  provides an overview of the KCL ID
BioBank. One additional significant property of this facil-
ity which should be highlighted is the high-degree of flex-
ibility engineered into the ethical permissions. This
means that it can be reactive to the emergence of new
pathogens. Plans are now being made for the collection of
samples from the anticipated second wave of the H1N1
('swine') influenza virus infections. In conclusion, whilst
the KCL ID BioBank currently holds fewer HIV samples
than its Spanish counterpart, it is an important and rap-
idly growing resource which will undoubtedly expedite
translational research of pathogens in the early part of the
21st century.
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